Genetic aberrations in the CDK4 pathway and association with innate resistance to PD-1 blockade in acral melanoma

被引：0
|
作者：
Yu, Jiayi
Kong, Yan
Chi, Zhihong
Tang, Bixia
Sheng, Xinan
Si, Lu
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.9588
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9588
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Coactivation of innate immune suppressive cells induces acquired resistance against combined TLR agonism and PD-1 blockade
    Nishinakamura, Hitomi
    Shinya, Sayoko
    Irie, Takuma
    Sakihama, Shugo
    Naito, Takeo
    Watanabe, Keisuke
    Sugiyama, Daisuke
    Tamiya, Motohiro
    Yoshida, Tatsuya
    Hase, Tetsunari
    Yoshida, Takao
    Karube, Kennosuke
    Koyama, Shohei
    Nishikawa, Hiroyoshi
    SCIENCE TRANSLATIONAL MEDICINE, 2025, 17 (785)
  • [42] Cancer-specific innate and adaptive immune rewiring drives resistance to PD-1 blockade in classic Hodgkin lymphoma
    Paczkowska, Julia
    Tang, Ming
    Wright, Kyle T.
    Song, Li
    Luu, Kelsey
    Shanmugam, Vignesh
    Welsh, Emma L.
    Weirather, Jason L.
    Besson, Naomi
    Olszewski, Harrison
    Porter, Billie A.
    Pfaff, Kathleen L.
    Redd, Robert A.
    Cader, Fathima Zumla
    Mandato, Elisa
    Ouyang, Jing
    Calabretta, Eleonora
    Bai, Gali
    Lawton, Lee N.
    Armand, Philippe
    Rodig, Scott J.
    Liu, Xiaole Shirley
    Shipp, Margaret A.
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [43] ASCO Annual Meeting 2021: News about PARP, PD-1 and CDK4 / 6 Inhibitors for the Treatment of Breast Cancer
    Emrich, Gerhard
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (7-8) : 422 - 423
  • [44] Human sulfatase 1 exerts anti-tumor activity by inhibiting the AKT/CDK4 signaling pathway in melanoma
    Lou, Xiaoli
    Sun, Bin
    Song, Jianxing
    Wang, Yicun
    Jiang, Junhao
    Xu, Yang
    Ren, Zeqiang
    Su, Changqing
    ONCOTARGET, 2016, 7 (51): : 84486 - 84495
  • [45] CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
    Ott, Patrick A.
    Hodi, F. Stephen
    Robert, Caroline
    CLINICAL CANCER RESEARCH, 2013, 19 (19) : 5300 - 5309
  • [46] Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models
    Wang, Qiaohong
    Gao, Jingze
    Di, Wen
    Wu, Xia
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (09) : 1781 - 1799
  • [47] Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models
    Qiaohong Wang
    Jingze Gao
    Wen Di
    Xia Wu
    Cancer Immunology, Immunotherapy, 2020, 69 : 1781 - 1799
  • [48] MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
    Rodig, Scott J.
    Gusenleitner, Daniel
    Jackson, Donald G.
    Gjini, Evisa
    Giobbie-Hurder, Anita
    Jin, Chelsea
    Chang, Han
    Lovitch, Scott B.
    Horak, Christine
    Weber, Jeffrey S.
    Weirather, Jason L.
    Wolchok, Jedd D.
    Postow, Michael A.
    Pavlick, Anna C.
    Chesney, Jason
    Hodi, F. Stephen
    SCIENCE TRANSLATIONAL MEDICINE, 2018, 10 (450)
  • [49] Systematic association analysis of immune checkpoint blockade of PD-1 by RNA-seq data in advanced melanoma patients
    Wang, Shu
    CANCER RESEARCH, 2018, 78 (13)
  • [50] Multiomic meta-analysis of differential response to PD-1 and CTLA-4 blockade in metastatic melanoma
    Huang, Amy Y.
    Vokes, Natalie
    Ricker, Cora
    Aprati, Tyler
    Robitschek, Emily
    Yang, Jiekun
    Ho, Li-Lun
    Galani, Kyriakitsa
    Burke, Kelly P.
    Tarantino, Giuseppe
    Chen, Jiajia
    Sharpe, Arlene H.
    Van Allen, Eliezer M.
    Kellis, Manolis
    Boland, Genevieve M.
    Liu, David
    CANCER RESEARCH, 2023, 83 (07)
12345